DXCM · Dexcom Inc · Executive Compensation
$84.86
-3.05 (-3.46%)
At close · Sep 8
Market Cap
$33.17B
Shares
377.36M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2025
| Executive | Role | Total |
|---|---|---|
| Kevin Sayer | Executive Chairman | $16,282,598 |
| Jacob Leach | President & Chief Executive Officer | $7,985,960 |
| Jereme Sylvain | EVP, Chief Financial Officer | $7,077,902 |
| Jon Coleman | EVP, Chief Commercial Officer | $6,745,295 |
| Michael Brown | EVP, Chief Legal Officer | $6,343,856 |
| Sadie Stern | EVP, Chief Human Resources Officer | $6,253,131 |
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Kevin Sayer | Executive Chairman | $15,828,797 |
| Kevin R. Sayer | Chairperson, President & Chief Executive Officer | $15,828,797 |
| Teri L. Lawver | Former EVP, Chief Commercial Officer | $6,452,827 |
| Jacob Leach | President & Chief Executive Officer | $5,922,271 |
| Jacob S. Leach | EVP, Chief Operating Officer | $5,922,271 |
| Jereme Sylvain | EVP, Chief Financial Officer | $5,851,112 |
| Michael Brown | EVP, Chief Legal Officer | $4,964,895 |
| Sadie M. Stern | EVP, Chief Human Resources Officer | $4,908,488 |
| Sadie Stern | EVP, Chief Human Resources Officer | $4,908,488 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Kevin R. Sayer | Chairperson, President & Chief Executive Officer | $15,712,244 |
| Kevin Sayer | Executive Chairman | $15,712,244 |
| Teri L. Lawver | Former EVP, Chief Commercial Officer | $6,526,593 |
| Jacob Leach | President & Chief Executive Officer | $4,938,023 |
| Jacob S. Leach | EVP, Chief Operating Officer | $4,938,023 |
| Michael Brown | EVP, Chief Legal Officer | $4,342,792 |
| Jereme Sylvain | EVP, Chief Financial Officer | $4,254,900 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Kevin R. Sayer | Chairperson, President & Chief Executive Officer | $15,435,652 |
| Kevin Sayer | CEO | $15,435,652 |
| Michael Brown | EVP, Chief Legal Officer | $5,746,278 |
| Jacob Leach | COO | $4,427,208 |
| Jacob S. Leach | EVP, Chief Operating Officer | $4,427,208 |
| Girish Naganathan | EVP, Chief Technology Officer | $4,051,531 |
| Jereme Sylvain | EVP, Chief Financial Officer | $3,538,881 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Kevin Sayer | CEO | $11,985,324 |
| Kevin R. Sayer | Chairperson, President & Chief Executive Officer | $11,985,324 |
| Jacob Leach | COO | $5,708,273 |
| Jacob S. Leach | EVP, Chief Operating Officer | $5,708,273 |
| Chad M. Patterson | EVP, Global Marketing | $4,875,133 |
| Paul Flynn | EVP, Global Revenue | $4,866,159 |
| Jereme Sylvain | EVP, Chief Financial Officer | $4,738,880 |
| Quentin Blackford | Former Chief Operating Officer and Former Chief Financial Officer | $4,621,854 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Kevin R. Sayer | Chairperson, President & Chief Executive Officer | $13,804,156 |
| Kevin Sayer | CEO | $13,804,156 |
| Jeffrey C. Moy | EVP, Operations | $7,478,553 |
| Richard B. Doubleday | EVP, Chief Commercial Officer | $5,853,342 |
| Quentin Blackford | Former Chief Operating Officer and Former Chief Financial Officer | $5,128,521 |
| Jacob Leach | COO | $4,370,582 |
| Jacob S. Leach | EVP, Chief Operating Officer | $4,370,582 |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| Kevin R. Sayer | Chairman, President & Chief Executive Officer | $10,279,373 |
| Kevin Sayer | CEO | $10,279,373 |
| Quentin Blackford | Former Chief Operating Officer and Former Chief Financial Officer | $3,806,896 |
| Richard B. Doubleday | EVP, Chief Commercial Officer | $3,274,184 |
| Andrew K. Balo | EVP, Regulatory Strategy, Clinical Affairs, and Strategic Partnership Development | $3,022,690 |
| Steven R. Pacelli | EVP, Strategy and Corporate Development | $3,020,341 |
Fiscal 2018
| Executive | Role | Total |
|---|---|---|
| Kevin R. Sayer | Chairman, President & Chief Executive Officer | $9,554,123 |
| Kevin Sayer | CEO | $9,554,123 |
| Quentin Blackford | Chief Operating Officer and Chief Financial Officer | $3,391,643 |
| Richard B. Doubleday | EVP, Chief Commercial Officer | $3,207,458 |
| Andrew K. Balo | EVP, Regulatory Strategy, Clinical Affairs, and Strategic Partnership Development | $3,174,638 |
| Steven R. Pacelli | EVP, Strategy and Corporate Development | $3,172,309 |
Fiscal 2017
| Executive | Role | Total |
|---|---|---|
| Kevin R. Sayer | Chairman, President and Chief Executive Officer | $7,924,868 |
| Kevin Sayer | CEO | $7,924,868 |
| Quentin Blackford | Chief Operating Officer and Chief Financial Officer | $5,115,201 |
| Andrew K. Balo | EVP, Regulatory Strategy, Clinical Affairs, and Strategic Partnership Development | $3,016,911 |
| Steven R. Pacelli | EVP, Strategy and Corporate Development | $2,919,155 |
| Richard B. Doubleday | EVP, Chief Commercial Officer | $2,919,155 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Kevin R. Sayer | Chief Executive Officer | Retired | 2026-03-02 |
| Kevin R. Sayer | Executive Chairman | Appointed | 2026-03-02 |
| Albert F. ("Rick") Osterloh, IV | member of the Compensation Committee and the Technology Committee of the Board | Appointed | 2026-02-26 |
| Albert F. ("Rick") Osterloh, IV | director | Appointed | 2026-02-26 |
| Jacob S. Leach | director | Appointed | 2025-12-22 |
| Kevin R. Sayer | Chief Executive Officer | Resigned | 2025-12-22 |
| Jacob S. Leach | President and Chief Executive Officer | Appointed | 2025-12-22 |
| Euan Ashley | director | Appointed | 2025-10-27 |
| Mark Foletta | interim chairman of the Board | Appointed | 2025-09-16 |
| Jacob S. Leach | director | Appointed | 2025-07-30 |
| Jacob S. Leach | President and Chief Executive Officer | Appointed | 2025-07-30 |
| Kevin R. Sayer | Executive Chairman of the Board | Appointed | 2025-07-30 |
| Kevin R. Sayer | Chief Executive Officer | Retired | 2025-07-30 |
| Jacob S. Leach | President and Chief Operating Officer | Appointed | 2025-05-13 |
| Karen Dahut | director | Resigned | 2025-05-02 |
Key facts
CIK
1093557
CUSIP
252131107
13F (30d)
489 filings
486 filers
Visit website
Investor relations